Literature DB >> 22822928

Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration.

Shuken Kai1, Eiji Kondo, Yasuyuki Kawaguchi, Nobuto Kitamura, Kazunori Yasuda.   

Abstract

AIM: To compare tissue concentrations of flurbiprofen resulting from topical application and oral administration according to the regulatory approved dosing guidelines.
METHOD: Sixteen patients were included in this study. Each patient was randomly assigned to the topical application or oral administration group. In each group, a pair of tapes or a tablet, containing a total of 40 mg flurbiprofen, was administered twice at 16 and 2 h before the surgery.
RESULTS: The flurbiprofen concentration in the fat, tendon, muscle and periosteum tissues was significantly higher (P < 0.0330) after topical application (992 ng g⁻¹ [95% CI 482, 1503], 944 [95% CI 481, 1407], 492 [95% CI 248, 735], and 455 [95% CI 153, 756], respectively) than after oral administration (150 ng g⁻¹ [95% CI 84, 217], 186 [95% CI 118, 254], 82 [95% CI 49, 116],and 221 [95% CI, 135, 307], respectively).
CONCLUSION: Topical application is an effective method to deliver flurbiprofen to the human body, particularly to soft tissues near the body surface.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22822928      PMCID: PMC3575946          DOI: 10.1111/j.1365-2125.2012.04394.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

2.  Modelling dermal drug distribution after topical application in human.

Authors:  Yuri G Anissimov; Michael Stephen Roberts
Journal:  Pharm Res       Date:  2011-04-27       Impact factor: 4.200

3.  Serum concentrations of flurbiprofen in rheumatoid patients receiving flurbiprofen over long periods of time.

Authors:  N Cardoe; M de-Silva; R C Glass; P C Risdall
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

Review 4.  The increasing need for nonoperative treatment of patients with osteoarthritis.

Authors:  J A Buckwalter; W D Stanish; R N Rosier; R C Schenck; D A Dennis; R D Coutts
Journal:  Clin Orthop Relat Res       Date:  2001-04       Impact factor: 4.176

5.  Flurbiprofen in post-partum women: plasma and breast milk disposition.

Authors:  I J Smith; J L Hinson; V A Johnson; R D Brown; S M Cook; R T Whitt; J T Wilson
Journal:  J Clin Pharmacol       Date:  1989-02       Impact factor: 3.126

6.  European experience with flurbiprofen. A new analgesic/anti-inflammatory agent.

Authors:  W W Buchanan; Y B Kassam
Journal:  Am J Med       Date:  1986-03-24       Impact factor: 4.965

7.  The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbiprofen LAT.

Authors:  W Bolten
Journal:  Br J Clin Pract       Date:  1994 Jul-Aug

8.  Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers.

Authors:  G Geisslinger; J Lötsch; S Menzel; G Kobal; K Brune
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

Review 9.  Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-12       Impact factor: 9.546

10.  Flurbiprofen at night.

Authors:  E C Huskisson; P J Scott; S Boyle; M Patrick
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

View more
  5 in total

1.  Editors' pick 2013.

Authors:  Albert Ferro; Yoon K Loke; Lionel D Lewis; Andrew Somogyi; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

2.  Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations.

Authors:  Ayse Nur Oktay; Sibel Ilbasmis-Tamer; Orhan Uludag; Nevin Celebi
Journal:  Pharm Res       Date:  2021-06-04       Impact factor: 4.200

3.  Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Authors:  Ikuko Yataba; Noboru Otsuka; Isao Matsushita; Miho Kamezawa; Ichimaro Yamada; Sigeru Sasaki; Kazuo Uebaba; Hideo Matsumoto; Yuichi Hoshino
Journal:  Eur J Clin Pharmacol       Date:  2015-10-06       Impact factor: 2.953

4.  Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.

Authors:  Natasja de Bruin; Ann-Kathrin Schneider; Philipp Reus; Sonja Talmon; Sandra Ciesek; Denisa Bojkova; Jindrich Cinatl; Imran Lodhi; Bruce Charlesworth; Simon Sinclair; Graham Pennick; William F Laughey; Philip Gribbon; Aimo Kannt; Susanne Schiffmann
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

5.  Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial.

Authors:  Masaki Amemiya; Yusuke Nakagawa; Hideya Yoshimura; Toru Takahashi; Kei Inomata; Tsuyoshi Nagase; Young-Jin Ju; Masayuki Shimaya; Sachiyuki Tsukada; Naoyuki Hirasawa; Hideyuki Koga
Journal:  Biopharm Drug Dispos       Date:  2021-09-29       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.